Familial Adenomatous Polyposis (FAP) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030


 Familial adenomatous polyposis (FAP) is an inherited condition that primarily affects the gastrointestinal tract. This condition causes hundreds or thousands of polyps to form inside the colon and rectum. This condition is also known as hereditary polyposis of the colorectum, Gardner's syndrome, and familial polyposis. Nearly 100% progression to colorectal cancer (CRC) by the age of 35–40 yr and a heightened risk of various other malignancies. Familial adenomatous polyposis (FAP) is a highly penetrant autosomal-dominant disorder caused by a germline mutation in the adenomatous polyposis coli (APC) gene chromosome 5q21. Over 700 different disease-causing APC mutations have been reported to date. However, the most common germline mutation involves the introduction of a premature stop codon, either by a nonsense mutation (30%), frameshift mutation (68%), or large deletion (2%), leading to truncation of the protein product in the C-terminal region.

 

The birth frequency of Familial adenomatous polyposis (FAP) in the USA and European populations is estimated at roughly 1.5 in 15,000 to 1.89 in 18,000 live births, respectively. It is also responsible for less than 1% of all CRC cases.

 

The competitive landscape of Familial Adenomatous Polyposis (FAP) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Familial Adenomatous Polyposis (FAP) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Familial Adenomatous Polyposis (FAP) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Familial Adenomatous Polyposis (FAP) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          REC-4881         Recursion         Phase 2

2          Encapsulated Rapamycin (eRapa)         Emtora Biosciences            Phase 2

3          Eicosapentaenoic acid free fatty acid (EPA-FFA) S.L.A. Pharma AG            Phase 3

4          Eflornithine        Cancer Prevention Pharmaceuticals, Inc.            Phase 3

5          celecoxib          Pfizer    Phase 1

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033